Enhancing CAR-T Cell Safety and Efficacy

​

FDA-approved chimeric antigen receptor (CAR)-T cell therapies hold great promise for cancer treatment but face significant challenges, including the lack of tumor-specific antigens, off-target toxicities, and tumor-mediated immunosuppression. To address these issues, we aim to develop an innovative gene circuit platform that integrates logic-gated antigen receptors, safety switches, and immunostimulatory payloads into a single system. This platform will enable precise control over CAR-T cell activation, differentiation, proliferation, and longevity, enhancing both safety and efficacy.

​

By improving specificity and expanding the therapeutic potential of CAR-T cells, this integrated approach will advance current pipelines and pave the way for effective treatment of solid tumors.

​